A Phase II Study to Treat Advanced Malignant Glioma

-subjects with documented histologically confirmed primary grade 4 advanced malignant glioma - no more than 3 prior relapses or prior systemic treatments - recurrent disease documented by MRI after prior therapy - must have at least one site of bidimensionally measurable disease: - archived tissue from the initial diagnosis of advanced malignant glioma or upon transformation to advanced malignant glioma are available for central review within approximately 4 weeks after enrollment - age ≥ 18 years - Karnofsky performance score ≥ 60% - hemoglobin ≥ 10 g/dL - absolute neutrophil count ≥ 1.5 x 10(9th)/L - platelet count ≥ 100 x 10(9th)/L - serum creatinine ≤ 1.5 times upper limit of normal - alanine aminotransferase ≤ 2.5 times upper limit of normal - serum total bilirubin ≤ 2.5 times upper limit of normal - before any study-specific procedure, the appropriate written informed consent must be obtained

- history of central nervous system bleeding as defined by stroke or intraocular bleed (including embolic stroke) within 6 months before enrollment - evidence of acute intracranial/intratumoral hemorrhage; except for subjects with stable grade 1 hemorrhage - received radiation therapy within 4 weeks before enrollment or have not recovered from the toxic effects of such therapy - treated previously with any c-Met or HGF targeted therapy - treated with thalidomide or tamoxifen within 1 week before enrollment or has not recovered from the toxic effects of such cancer therapy - treated with immunotherapeutic agents, vaccines or mAb therapy within 4 weeks before enrollment or have not recovered from the toxic effects of such cancer therapy - treated with alkylating agents within 4 weeks before enrollment or has not recovered from the toxic effects of such cancer therapy - treated with chemotherapy (non-alkylating agents) within 2 weeks before enrollment or has not recovered from the toxic effects of such cancer therapy - surgical resection of brain tumor within 4 weeks before enrollment or have not recovered from acute side effects of such therapy, except for neurological effects - plans to receive surgery, radiation therapy or other elective surgeries during the course of the study - concurrent severe and/or uncontrolled medical disease (e.g., uncontrolled diabetes, congestive cardiac failure, myocardial infarction within 6 months before enrollment) that could compromise participation in the study - active infection within 7 days before enrollment - past or current history of another neoplasm, except for curatively treated non-melanoma skin cancer, carcinoma in situ of the cervix and other primary solid cancer with no known active disease present and no curative or adjuvant treatment administered for the last 3 years - documented history of human immunodeficiency virus - documented history of chronic viral hepatitis - concurrent or prior (within 7 days of enrollment) anticoagulation therapy, except: * Use of low molecular weight heparins (LMWH, e.g., enoxaparin sodium [Lovenox] and unfractionated heparin for prophylaxis against central venous catheter thrombosis is allowed * Use of low dose warfarin (< 2 mg/day) for prophylaxis against central venous catheter thrombosis is allowed - currently enrolled in or has not yet completed at least 30 days since ending other investigational device or therapeutic study(s) - had major surgery within 4 weeks before enrollment or recovering from prior surgery - known allergy or sensitivity to any of the excipients in the investigational product - pregnant or breast feeding - unwilling to use adequate contraceptive precautions during the course of the study and for 6 months after the last administration of investigational product, for: * male subjects * female subjects who are not post-menopausal (no menstrual period for a minimum of 12 months at study entry) or documented surgically sterile will not be bound to this exclusion - previously treated with AMG 102 - previously enrolled into this study - will not be available for follow-up assessment - has other disorders that compromises the ability of the subject to give written informed consent and/or comply with study procedures